ReviewCureus2025
Chimeric Antigen Receptor-Engineered Natural Killer (CAR-NK) Cell Therapy in Acute Myeloid Leukemia: A Systematic Review of the Literature.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chimeric antigen receptor (CAR)-engineered natural killer (NK) cells are attracting considerable interest as a potential therapeutic option in acute myeloid leukemia (AML), driven by the search for safe, scalable, and effective alternatives. To provide an overview of the current state of the field, a systematic review was performed to evaluate the safety and efficacy of CAR-NK cells for AML. The findings suggest possible directions for future development and also highlight important obstacles that must be addressed before they can be used in clinical settings. Therefore, although CAR-NK therapy remains in its early stages, its eventual application in AML is possible if these barriers can be resolved.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.